<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR106">
 <label>106.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hashizume</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Tan</surname>
    <given-names>SL</given-names>
   </name>
   <name>
    <surname>Takano</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Ohsawa</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Hasada</surname>
    <given-names>I</given-names>
   </name>
   <name>
    <surname>Hanasaki</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Ito</surname>
    <given-names>I</given-names>
   </name>
   <name>
    <surname>Mihara</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Nishida</surname>
    <given-names>K</given-names>
   </name>
  </person-group>
  <article-title>Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights</article-title>
  <source>Int Rev Immunol</source>
  <year>2015</year>
  <volume>34</volume>
  <issue>3</issue>
  <fpage>265</fpage>
  <lpage>279</lpage>
  <?supplied-pmid 25099958?>
  <pub-id pub-id-type="pmid">25099958</pub-id>
 </element-citation>
</ref>
